Laxmi Dental CEO, MD, chairman, board of directors and AGM
NSE: LAXMIDENTLBSE: 544339Healthcare Equipment & SuppliesSmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹176.69.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹937 Cr1,414th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 30.3
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹5.78 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 25.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 21 May 2026
- 3.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 13.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹5.78 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 16.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 21 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,18,47951.1% delivered
Laxmi Dental board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonRAJESH VRAJLAL KHAKHARRelated to the promoter
- Managing director and CEOSAMEER KAMLESH MERCHANT
- Company Secretary and Compliance OfficerSUMAN SAHA
6 directors3 independent2 executive1 non-executive
- RAJESH VRAJLAL KHAKHAR · ChairpersonExecutive · joined Jul 2004 · 1 listed board · 1 committee seat
- SAMEER KAMLESH MERCHANT · Managing director and CEOExecutive · joined Jul 2004 · 1 listed board · 2 committee seats
- ANIL TILAKRAJ ARORANon-executive · joined Aug 2025 · 2 listed boards · 1 as independent
- RAJESH SHASHIKANT DALALIndependent · joined Jul 2024 · 23 months as independent · 3 listed boards · 3 as independent · 5 committee seats, 1 as chair
- ANJANA GREWALIndependent · joined Jul 2024 · 23 months as independent · 1 listed board · 1 as independent · 1 committee seat
- DEVESH GHANSHYAM CHAWLAIndependent · joined Jul 2024 · 23 months as independent · 1 listed board · 1 as independent · 2 committee seats, 2 as chair
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
1 director who left
- SUMONA CHAKRABORTY, left 7 Jun 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 21 May 20265 of 6 present3 independent · 13 days in between
- 7 May 20266 of 6 present3 independent · 41 days in between
- 26 Mar 20265 of 6 present2 independent · 43 days in between
- 10 Feb 20265 of 6 present3 independent · 24 days in between
1 earlier meeting
- 16 Jan 20266 of 6 present3 independent
Audit Committee
Chair DEVESH GHANSHYAM CHAWLA
RAJESH SHASHIKANT DALAL, SAMEER KAMLESH MERCHANT, ANJANA GREWAL
- 21 May 20264 of 4 present3 independent · 13 days in between
- 7 May 20264 of 4 present3 independent · 85 days in between
- 26 Mar 20263 of 4 present2 independent · 43 days in between
- 10 Feb 20264 of 4 present3 independent
Nomination and remuneration committee
Chair RAJESH SHASHIKANT DALAL
ANJANA GREWAL, DEVESH GHANSHYAM CHAWLA
- 26 Mar 20262 of 3 present2 independent · 68 days in between
- 16 Jan 20263 of 3 present3 independent
Stakeholders Relationship Committee
Chair DEVESH GHANSHYAM CHAWLA
RAJESH VRAJLAL KHAKHAR, SAMEER KAMLESH MERCHANT
- 10 Feb 20263 of 3 present1 independent
Corporate Social Responsibility Committee
Chair RAJESH VRAJLAL KHAKHAR
SAMEER KAMLESH MERCHANT, ANJANA GREWAL
- 26 Mar 20263 of 3 present1 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- M S K A & AssociatesPeer-review certificate valid to Jul 2027
1 earlier auditor
- M S K A & Associates LLPNamed in the filing for the quarter to Dec 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Laxmi Dental AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Laxmi Dental share news and announcements
Annual general meeting, 25 Sep 2026
37,331 shareholders on the register on 18 Sep 2026; present: 3 promoters and 52 others; votes counted by Muffaddal Jawadwala / M. Jawadwala & Co.The company's voting result (opens in a new tab)
1 - Adoption of Audited Standalone Financial Statements of the Company for the financial year ended 31 March, 2026, including the Audited Balance Sheet as on that date, the Statement of Profit and Loss and Cash Flow Statement for the financial year ended on that date together with the Reports of the Board of Directors and Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 87.02% · promoters 100.00% · institutions 97.08% · other public 69.52%
2 - Adoption of Audited Consolidated Financial Statements of the Company for the financial year ended 31 March, 2026, including the Audited Balance Sheet as on that date, the Statement of Profit and Loss and Cash Flow Statement for the financial year ended on that date together with the Report of the Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 87.02% · promoters 100.00% · institutions 97.08% · other public 69.52%
- 3 - Re-appointment of Mr. Rajesh Vrajlal Khakhar (DIN: 00679903), Whole-time Director, as a Director liable to retire by rotation and, being eligible, offers himself for re-appointment.Ordinary99.96% for0.04% against
Against: promoters 0.00% · institutions 0.13% · other public 0.00%
Turnout: all 62.26% · promoters 40.70% · institutions 97.08% · other public 69.52%
- 4 - Approval for variation in the objects/terms of utilization of the Initial Public Offering (“IPO”) proceeds and extension of the timeline for utilization of IPO Proceeds.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.01% · other public 0.00%
Turnout: all 87.02% · promoters 100.00% · institutions 97.08% · other public 69.52%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 29 Sep 2025, 6 resolutions
38,090 shareholders on the register on 22 Sep 2025; present: 6 promoters and 29 others; votes counted by Mr. Muffaddal Jawadwala / M/s. M. Jawadwala & Co..The company's voting result (opens in a new tab)
Adoption of the Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2025, including the Audited Balance Sheet as on that date, the Statement of Profit and Loss and Cash Flow Statement for the financial year ended on that date together with the Reports of the Board of Directors and Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 90.42% · promoters 100.00% · institutions 96.21% · other public 44.03%
Adoption of the Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2025, including the Audited Balance Sheet as on that date, the Statement of Profit and Loss and Cash Flow Statement for the financial year ended on that date together with the Report of the Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 90.42% · promoters 100.00% · institutions 96.21% · other public 44.03%
- Re-Appointment of Mr. Sameer Kamlesh Merchant (DIN: 00679893), Managing Director, as a director liable to retire by rotation and, being eligible, offers himself for re-appointment.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.03%
Turnout: all 90.42% · promoters 100.00% · institutions 96.21% · other public 44.03%
- Re-appointment of M/s. M. Jawadwala & Co, Practicing Company Secretaries as Secretarial Auditors of the Company for a period of up-to five (5) consecutive years and to fix the remuneration thereof.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.03%
Turnout: all 90.42% · promoters 100.00% · institutions 96.21% · other public 44.03%
- Appointment of Dr Anil Arora (DIN: 03469947) as Non-Executive, Non-Independent Director.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.02%
Turnout: all 90.42% · promoters 100.00% · institutions 96.21% · other public 44.03%
- Amendments to the existing Laxmi Dental Stock Option Scheme 2024 (“ESOP Scheme”), for amendment of Authority and Ceiling Clause of the Scheme.Special94.44% for5.56% against
Against: promoters 0.00% · institutions 11.84% · other public 0.02%
Turnout: all 90.42% · promoters 100.00% · institutions 96.21% · other public 44.03%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 17 May 2025, 1 resolution
30,178 shareholders on the register on 11 Apr 2025; votes counted by Muffaddal Jawadwala / M. Jawadwala & Co.The company's voting result (opens in a new tab)
- Ratification of Employee Stock Option Scheme 2024 of Laxmi Dental LimitedSpecial82.36% for17.64% against
Against: promoters 0.00% · institutions 83.47% · other public 0.00%
Turnout: all 89.16% · promoters 100.00% · institutions 76.36% · other public 85.11%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
How mutual funds voted
Fund houses must disclose how they vote at every meeting of a company they hold.Funds that hold it
Mutual fund votes, meeting of 25 Sep 2026, 3 fund houses so far (houses' deadline to file 15 Oct 2026)
1 - Adoption of Audited Standalone Financial Statements of the Company for the financial year ended 31 March, 2026, including the Audited Balance Sheet as on that date, the Statement of Profit and Loss and Cash Flow Statement for the financial year ended on that date together with the Reports of the Board of Directors and Auditors thereon.MoreLess
3 for0 against2 - Adoption of Audited Consolidated Financial Statements of the Company for the financial year ended 31 March, 2026, including the Audited Balance Sheet as on that date, the Statement of Profit and Loss and Cash Flow Statement for the financial year ended on that date together with the Report of the Auditors thereon.MoreLess
3 for0 against- 3 - Re-appointment of Mr. Rajesh Vrajlal Khakhar (DIN: 00679903), Whole-time Director, as a Director liable to retire by rotation and, being eligible, offers himself for re-appointment.3 for0 against
- 4 - Approval for variation in the objects/terms of utilization of the Initial Public Offering (“IPO”) proceeds and extension of the timeline for utilization of IPO Proceeds.3 for0 against
Mutual fund votes, meeting of 29 Sep 2025, 13 fund houses
Adoption of the Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2025, including the Audited Balance Sheet as on that date, the Statement of Profit and Loss and Cash Flow Statement for the financial year ended on that date together with the Reports of the Board of Directors and Auditors thereon.MoreLess
13 for0 againstAdoption of the Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2025, including the Audited Balance Sheet as on that date, the Statement of Profit and Loss and Cash Flow Statement for the financial year ended on that date together with the Report of the Auditors thereon.MoreLess
13 for0 against- Re-Appointment of Mr. Sameer Kamlesh Merchant (DIN: 00679893), Managing Director, as a director liable to retire by rotation and, being eligible, offers himself for re-appointment.13 for0 against
- Re-appointment of M/s. M. Jawadwala & Co, Practicing Company Secretaries as Secretarial Auditors of the Company for a period of up-to five (5) consecutive years and to fix the remuneration thereof.13 for0 against
- Appointment of Dr Anil Arora (DIN: 03469947) as Non-Executive, Non-Independent Director.13 for0 against
- Amendments to the existing Laxmi Dental Stock Option Scheme 2024 (“ESOP Scheme”), for amendment of Authority and Ceiling Clause of the Scheme.
Against Aditya Birla Sun Life Mutual Fund, Bandhan Mutual Fund, Bank of India Mutual Fund, HDFC Mutual Fund, Kotak Mahindra Mutual Fund, LIC Mutual Fund, Mirae Asset Mutual Fund, Motilal Oswal Mutual Fund, UTI Mutual Fund
- Aditya Birla Sun Life Mutual Fund, Bank of India Mutual Fund, UTI Mutual FundThe company proposes to amend the ESOP scheme to remove the limit of 50,000 options to an employee in aggregate. Annual cap of 50,000 options per employee per annum will continue. This will allow for a greater skew in the distribution of grants. Therefore, we do not support the amendment. Further, we do not support the ESOP 2024 scheme, as options can be granted to employees at a price as decided by the board and can be as low as the face of the shares – stock options are ‘pay at risk’ options that employees accept at the time of grant. In the case of deeply discounted options, there is no alignment between the interests of investors and those of employees. We do not support the resolution.
- Bandhan Mutual Fund, Motilal Oswal Mutual FundAlthough no concern has been identified in the proposed variation in the scheme. However, Compliance Concern identified under the original ESOP Scheme to which variation is proposed.
- HDFC Mutual FundThe company proposes to amend the ESOP scheme to remove the limit of 50,000 options to an employee in aggregate. Annual cap of 50,000 options per employee per annum will continue. This will allow for a greater skew in the distribution of grants. Further, the options are granted at a deep discount to market price. We do not support the resolution.
- Kotak Mahindra Mutual FundThis amendment in existing ESOP scheme would allow an employee to receive more than 50,000 options in aggregate, with restriction of maximum of 50,000 during a year. As company has not put upper limit for the options for an individual employee, This will allow for a greater skew in the distribution of grants. Considering this governance concern, we do not favour the resolution.
- LIC Mutual FundCompliance Concern identified under the original ESOP Scheme to which variation is proposed.
- Mirae Asset Mutual FundESOP at steep discount to market price do not align with shareholder interest
4 for9 against
1 earlier meeting
Mutual fund votes, meeting of 17 May 2025, 15 fund houses
- Ratification of Employee Stock Option Scheme 2024 of Laxmi Dental Limited
Against Aditya Birla Sun Life Mutual Fund, Bandhan Mutual Fund, Bank of India Mutual Fund, Edelweiss Mutual Fund, HDFC Mutual Fund, HSBC Mutual Fund, Invesco Mutual Fund, Kotak Mahindra Mutual Fund, Mirae Asset Mutual Fund, quant Mutual Fund, Tata Mutual Fund, UTI Mutual Fund
- Aditya Birla Sun Life Mutual Fund, Bank of India Mutual Fund, Invesco Mutual FundUnder ESOP 2024, the company can grant upto 500,000 options through fresh issue of shares. Of these, 351,672 options were granted at face value till the date of the prospectus. The exercise price under the scheme is unclear as it will be determined by the board. If granted at face value, it represents a discount of ~99.5% to the prevailing market price. We do not favour ESOP schemes where options are granted at a significant discount (>20%) to market price as stock options are ‘pay at risk’ options that employees accept at the time of grant. In the case of deeply discounted options, there is no alignment between the interests of investors and those of employees. We make an exception where the vesting of such options is mandatorily linked to performance parameters and the company has disclosed the pre-defined performance targets for such parameters. In the current case, the vesting of options is primarily time-based. In addition, the Nomination and Remuneration Committee (NRC) may determine certain performance criteria for vesting. However, such performance parameters along with the targets have not been articulated. In the absence of clarity and the flexibility extended to the NRC, we do not support the resolution.
- Bandhan Mutual FundNon-Compliant under SEBI SBEB Regulations: Inadequate disclosure w.r.t Exercise Price; Absolute Discretion to NRC to determine Exercise Price.
- Edelweiss Mutual FundNon-Compliant under SEBI SBEB Regulations: Inadequate disclosure w.r.t Exercise Price; Absolute Discretion to NRC to determine Exercise Price. Transparency Concern: Separate approval is required to grant options to subsidiaries’ employees and it is unclear whether the Company intends to grant options to subsidiaries’ employees.
- HDFC Mutual FundLack of clarity on the pricing of ESOPS. We do not support the resolution.
- HSBC Mutual FundA vote AGAINST this resolution is warranted because: • The stock options may be issued with an exercise price at a discount to the prevailing market price, on the date of grant. • The vesting can also be based on achievement of performance conditions, set by the NRC. However, the company has not specified the performance parameters, targets and thresholds for vesting.
- Kotak Mahindra Mutual FundUnder ESOP 2024, the company can grant up to 500,000 options through fresh issue of shares. Of these, 351,672 options were granted at face value till the date of the prospectus. The company has not provided the exercise price under the scheme and has provided NRC the Discretion to determine the Exercise Price. Performance parameters along with the targets also have not been articulated. In the absence of clarity and the flexibility extended to the NRC, we do not support the resolution.
- Mirae Asset Mutual FundESOP pricing at significant discount to market price (high discount implies non-alignment of potential future growth for shareholder and ESOP holders)
- quant Mutual FundRelated to the ratification of the company’s 2024 ESOP scheme. Despite our proxy advisor having raised concern with the company, the NRC has retained absolute & full discretion to determine Exercise Price. Such non-disclosure or authorizing Board/ NRC to solely decide such price defeats the purpose of SEBI mandated disclosures. We believe that a pricing formula (As envisaged under the Part C Schedule I of the Regulations) should be disclosed by the NRC to uphold the intended objective of the Regulator to allow shareholders to estimate the economic benefit proposed to be transferred to its employees during the course of time. Hence, we are voting against the resolution.
- Tata Mutual FundWe do not favor ESOP schemes where options are granted at a significant discount to market price as stock options are ‘pay at risk’ options that employees accept at the time of grant. In the case of deeply discounted options, there is no alignment between the interests of investors and those of employees. As per our discussion with the company ESOPs shall be granted at Face Value and not linked to performance. Hence we do not support such resolution.
- UTI Mutual FundUnder ESOP 2024, the company can grant upto 500,000 options through fresh issue of shares. Of these, 351,672 options were granted at face value till the date of the prospectus. The exercise price under the scheme is unclear as it will be determined by the board. If granted at face value, it represents a discount of ~99.5% to the prevailing market price. We do not favour ESOP scheme as there is lack of clarity in terms of performance-criteria for the grant of ESOPS and the vesting of options is primarily time-based. In addition, the Nomination and Remuneration Committee (NRC) may determine certain performance criteria for vesting. However, such performance parameters along with the targets have not been articulated. In the absence of clarity, We do not support the resolution.
3 for12 against
Each fund house counted once, from its own disclosure; the reasons are its own words.
Fines and tax disputes
Reported in the filing for the quarter to Jun 2026.
- Fine or penaltyNational Stock Exchange of India LimitedSince 5 May 2026
Decision letter of NSE Waiver Committee
After considering the Company’s submissions, the Committee, not being satisfied with the response, rejected the request for waiver of the fine and directed the Company to remit ₹2,18,300/- (including GST) on or before May 15, 2026.MoreLess
- Tax disputeGST - Tax OfficerSince 18 Oct 2025No change in status from last disclosureAt the filing before: same as last quarter
- Tax disputeDepartment of Goods & Services TaxSince 30 Dec 2024No change in status from last disclosureAt the filing before: same as last quarter
- Tax disputeAssessment Unit Income Tax DepartmentSince 21 Mar 2025As per the order of Assistant Commissioner of Income tax dated 17-04-2026 it has been determined that a sum of Rs. 0/- for the Assessment year 2019-20 is payable to the CompanyAt the filing before: same as last quarter
- Tax disputeDepartment of Goods & Services TaxSince 26 Feb 2026same as last quarterAt the filing before: We have received Notice to conduct the audit but there is no liability or Demand is determined/quantified. Audit will be conducted in/after the month June 2026 as extention is requested.
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- Yes
- The filing has a part on tax disputes
- Yes
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2026.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Public IssuesJan 2025, checked by ICRA LIMITED | 698.06 | Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by our Company | 22.98 | 22.98 | No |
| Public IssuesJan 2025, checked by ICRA LIMITED | 698.06 | Investment in certain Subsidiaries for the repayment/prepayment, in full or in part, of certain outstanding borrowings. | 4.60 | 4.60 | No |
| Public IssuesJan 2025, checked by ICRA LIMITED | 698.06 | Funding the capital expenditure requirements for purchase of new machinery for our Company. | 43.51 | 15.72 | No |
| Public IssuesJan 2025, checked by ICRA LIMITED | 698.06 | Investment in our Subsidiary, Bizdent Devices Private Limited, for the capital expenditure requirements for the purchase of new machinery. | 25.00 | 2.59 | No |
| Public IssuesJan 2025, checked by ICRA LIMITED | 698.06 | General corporate purposes. | 32.08 | 32.08 | No |